Results 71 to 80 of about 133,537 (299)
Journal of experimental & clinical cancer research : CR, 2021 Background Resistance to oxaliplatin is a major obstacle for the management of locally advanced and metastatic colon cancer (CC). Although long noncoding RNAs (lncRNAs) play key roles in CC, the relationships between lncRNAs and resistance to oxaliplatin
Qingguo Li +13 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source
Gabapentin Prevents Oxaliplatin-Induced Mechanical Hyperalgesia in Mice
Journal of Pharmacological Sciences, 2014 .: Oxaliplatin, a platinum-based chemotherapy drug, frequently causes acute and chronic peripheral neuropathies including mechanical hyperalgesia. These adverse effects hinder anticancer therapy with the drug.
Masahiro Ohsawa +5 more
doaj +1 more source
Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. [PDF]
, 2015 Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer.
Herman, June +3 more
core +3 more sources
Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer
Molecular Cancer, 2019 Oxaliplatin resistance is a major challenge for treatment of advanced colorectal cancer (CRC). Both acquisition of epithelial-mesenchymal transition (EMT) and suppressed drug accumulation in cancer cells contributes to development of oxaliplatin ...
Tong Liu +12 more
semanticscholar +1 more source
Effect of chemotherapy on passenger mutations in metastatic colorectal cancer
Molecular Oncology, EarlyView.Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui +6 more
wiley +1 more source
Hepatology, EarlyView., 2022 Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou +13 more
wiley +1 more source
Strength through diversity: how cancers thrive when clones cooperate
Molecular Oncology, EarlyView.Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken +3 more
wiley +1 more source
Oxaliplatin combined with daunorubicin induces apoptosis of colon cancer cell line HT-29 [PDF]
Jichu yixue yu linchuang, 2020 Objective To study the mechanism of oxaliplatin combined with daunorubicin on the apoptosis of colon cancer cells. Methods Colon cancer cells HT-29 were incubated with different concentrations of oxaliplatin and daunorubicin respectively, MTT assay was ...
TIAN Chun-yang, LIU Xiao-zheng, FAN Jun-chao
doaj
BMC Cancer, 2020 Background Chemo-resistance in hepatocellular carcinoma (HCC) is a major problem, and acquired drug resistance prevents cancer therapies from achieving complete responses.
Xia Liao +9 more
doaj +1 more source